Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Journey Medical (DERM) Depreciation & Amortization (CF) (2020)

Journey Medical filings provide 1 years of Depreciation & Amortization (CF) readings, the most recent being $1000.0 for Q4 2020.

On a quarterly basis, Depreciation & Amortization (CF) changed N/A to $1000.0 in Q4 2020 year-over-year; TTM through Sep 2021 was $1000.0, a N/A change, with the full-year FY2020 number at $5000.0, changed N/A from a year prior.
Depreciation & Amortization (CF) hit $1000.0 in Q4 2020 for Journey Medical, roughly flat from $1000.0 in the prior quarter.
In the past five years, Depreciation & Amortization (CF) ranged from a high of $1000.0 in Q3 2020 to a low of $1000.0 in Q3 2020.